Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TriACT: Triple Combination Antiviral for COVID-19
NCT04605588Phase 2Terminated
- Sponsor
- Rutgers University
- Start
- Dec 2020
- Primary completion
- Jan 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nitazoxanide, ribavirin and hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Rutgers University. Primary endpoint: Rate of Decline in Viral Load Over the 10 Days After Randomization. Started Dec 2020; status: terminated.
02
Drugs
nitazoxanideribavirinhydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04605588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04605588.